Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SP16 as a Therapeutic for SARS-CoV-2 Induced ARDS

NCT05135624 is registered in ClinicalTrials.gov with Serpin Pharma, LLC as lead sponsor.

NCT NCT05135624
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05135624 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SP16 as a Therapeutic for SARS-CoV-2 Induced ARDS
Lead sponsor
Serpin Pharma, LLC
Phase
Phase 1
Overall status
Terminated
Start date
December 1, 2021
Completion date
June 30, 2023
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pneumonia, sars cov 2 infection